The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Involvement of pp60c-src with two major signaling pathways in human breast cancer.
Open accessAbstract
The phosphotyrosine residues of receptor tyrosine kinases serve as unique binding sites for proteins involved in intracellular signaling, which contain SRC homology 2 (SH2) domains. Since overexpression or activation of the pp60c-src kinase has been reported in a number of human tumors, including primary human breast carcinomas, we examined the interactions of the SH2 and SH3 domains of human SRC with target proteins in human carcinoma cell lines. Glutathione S-transferase fusion proteins containing either the SH2, SH3, or the entire SH3/SH2 region of human SRC were used to affinity purify tyrosine-phosphorylated proteins from human breast carcinoma cell lines. We show here that in human breast carcinoma cell lines, the SRC SH2 domain binds to activated epidermal growth factor receptor (EGFR) and p185HER2/neu. SRC SH2 binding to EGFR was also observed in a nontumorigenic cell line after hormone stimulation. Endogenous pp60c-src was found to tightly associate with tyrosine-phosphorylated EGFR. Association of the SRC SH2 with the EGFR was blocked by tyrosyl phosphopeptides containing the sequences surrounding tyrosine-530, the regulatory site in the SRC C terminus, or sequences surrounding the major sites of autophosphorylation in the EGFR. These results raise the possibility that association of pp60c-src with these receptor tyrosine kinases is an integral part of the signaling events mediated by these receptors and may contribute to malignant transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
SH2 domains recognize specific phosphopeptide sequences
Zhou, S. (1993) · Cell · doi:10.1016/0092-8674(93)90404-e · Cited by 2,631
SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signaling Proteins
Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., & Pawson, T. (1991) · Science · doi:10.1126/science.1708916 · Cited by 1,868
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., & Weinberg, R. A. (1984) · Nature · doi:10.1038/312513a0 · Cited by 1,175
Association between the PDGF receptor and members of the src family of tyrosine kinases
Kypta, R. M., Goldberg, Y., Ulug, E. T., & Courtneidge, S. A. (1990) · Cell · doi:10.1016/0092-8674(90)90013-5 · Cited by 635
Semba, K., Kamata, N., Toyoshima, K., & Yamamoto, T. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6497 · Cited by 598
Ottenhoff-Kalff, A. E., Rijksen, G., van Beurden, E. A., Hennipman, A., Michels, A. A., & Staal, G. E. J. (1992) · PubMed · Cited by 348
Filmus, J., Pollak, M. N., Cailleau, R., & Buick, R. N. (1985) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(85)90131-7 · Cited by 338
Cited by
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
“In addition, activation of c-Src also occurs with elevated frequency during progression of human breast cancer (Ottenho - Kal et al., 1992) and has been associated with constitutive activation of HER1 and HER2 proteins (Luttrell et al., 1994; Muthuswamy and Muller, 1995).”
BackgroundConstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.
Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., & Auricchio, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00471.x · Cited by 959
Role of Src expression and activation in human cancer
Irby, R. B., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 857
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204349 · Cited by 756
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
Eguchi, S., Numaguchi, K., Iwasaki, H., Matsumoto, T., Yamakawa, T., Utsunomiya, H., Motley, E. D., Kawakatsu, H., Owada, K. M., Hirata, Y., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.15.8890 · Cited by 566
Receptor-tyrosine-kinase- and Gβγ-mediated MAP kinase activation by a common signalling pathway
Blesen, T. V., Hawes, B. E., Luttrell, D. K., Krueger, K. M., Touhara, K., Porfflri, E., Sakaue, M., Luttrell, L. M., & Lefkowitz, R. J. (1995) · Nature · doi:10.1038/376781a0 · Cited by 541
Self-citationBiochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Luttrell, L. M., Hawes, B. E., van Biesen, T., Luttrell, D. K., Lansing, T. J., & Lefkowitz, R. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19443 · Cited by 525
Self-citationMechanism of biological synergy between cellular Src and epidermal growth factor receptor
Tice, D. A., Biscardi, J. S., Nickles, A. L., & Parsons, S. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1415 · Cited by 472
Gβγ Subunits Mediate Src-dependent Phosphorylation of the Epidermal Growth Factor Receptor
Luttrell, L. M., Rocca, G. J. D., van Biesen, T., Luttrell, D. K., & Lefkowitz, R. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4637 · Cited by 457
Self-citationThe interplay between Src family kinases and receptor tyrosine kinases
Bromann, P. A., Korkaya, H., & Courtneidge, S. A. (2004) · Oncogene · doi:10.1038/sj.onc.1208079 · Cited by 454
Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways
Parsons, J. T., & Parsons, S. J. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80062-2 · Cited by 392
ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases
Olayioye, M. A., Beuvink, I., Horsch, K., Daly, J. M., & Hynes, N. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17209 · Cited by 367
Mitogenic signaling via G protein-coupled receptors
van BIESEN, T., LUTTRELL, L. M., HAWES, B. E., & LEFKOWITZ, R. J. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-6-698 · Cited by 361
Maa, M. C., Leu, T. H., McCarley, D. J., Schatzman, R. C., & Parsons, S. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6981 · Cited by 330
Biscardi, J. S., Ishizawar, R. C., Silva, C. M., & Parsons, S. J. (2000) · Breast Cancer Research · doi:10.1186/bcr55 · Cited by 323
Bjorge, J. D., Pang, A., & Fujita, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004852200 · Cited by 316
Tyrosine phosphorylation and cadherin/catenin function
Daniel, J. M., & Reynolds, A. B. (1997) · BioEssays · doi:10.1002/bies.950191008 · Cited by 313
Src family protein tyrosine kinases and cellular signal transduction pathways
Erpel, T., & Courtneidge, S. A. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80025-5 · Cited by 294
Mader, C. C., Oser, M., Magalhaes, M. A. O., Bravo-Cordero, J. J., Condeelis, J., Koleske, A. J., & Gil-Henn, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1432 · Cited by 294
Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain
Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., Liewehr, D. J., Steinberg, S. M., Merino, M. J., Rubin, S. D., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn216 · Cited by 283
Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases
Osherov, N., & Levitzki, A. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.1047b.x · Cited by 281
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner
Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., & Hynes, N. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5042 · Cited by 262
Li, Q., Kuwahara, H., Yin, L., Li, Y., Ren, J., Yu, W.-H., Carraway, K. L., & Kufe, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100359200 · Cited by 257
Xia, W., Liu, L.-H., Ho, P., & Spector, N. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207166 · Cited by 253
Current status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A. (2020) · Cancers · doi:10.3390/cancers12061448 · Cited by 139
“In HER2-negative bone-prevalent metastatic patients partial responses in bone were noted in 23% of patient (25 total), all with HR-positive cancers, in combination with zolendronic acid [116].”
InfluentialRexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
Zheng, X., Resnick, R. J., & Shalloway, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23321 · Cited by 60
Degradation of HER2 by Cbl-Based Chimeric Ubiquitin Ligases
Li, X., Shen, L., Zhang, J., Su, J., Shen, L., Liu, X., Han, H., Han, W., & Yao, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3731 · Cited by 37
SRC at the Crossroads of KRAS Inhibitor Resistance: Mechanisms and Therapeutic Opportunities
Tian, H., Zhao, D., Zhou, Z., Kim, A., Huang, H., Lee, Y. J., Qu, Z., Kang, R., Zeh, H. J., Westover, K. D., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2025.218194 · Cited by 7
Metadata
- Authors
- Luttrell, D. K., Lee, A., Lansing, T. J., Crosby, R. M., Jung, K. D., Willard, D., Luther, M., Rodriguez, M., Berman, J., & Gilmer, T. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-01-04
- Volume
- 91
- Issue
- 1
- Pages
- 83-87
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2091656640
- Cited by
- 271
- References
- 25
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.